Related Experiment Videos
Allopurinol as a cardiovascular drug
Anita Kelkar1, Allen Kuo, William H Frishman
1Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Cardiology in Review
|October 11, 2011
Summary
Elevated uric acid increases cardiovascular disease (CVD) risk. Allopurinol, a uric acid-lowering drug, shows potential in treating CVD by reducing oxidative stress and improving heart function.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Cardiovascular disease (CVD) is a leading cause of death.
- Elevated uric acid levels are linked to increased cardiovascular (CV) event risk.
- Xanthine oxidase activity contributes to uric acid formation and oxidative stress.
Purpose of the Study:
- To review the pharmacologic action of allopurinol on the cardiovascular system.
- To evaluate allopurinol's effectiveness in treating ischemic heart disease and congestive heart failure.
- To explore allopurinol as a potential cardiovascular drug.
Main Methods:
- Review of clinical studies and biochemical research on uric acid and allopurinol.
- Analysis of allopurinol's mechanism as a xanthine oxidase inhibitor and free radical scavenger.
- Examination of allopurinol's effects on endothelial function, oxidative stress, and heart failure parameters.
Main Results:
- Allopurinol inhibits xanthine oxidase, reducing uric acid production and associated free radicals.
- Allopurinol improves endothelial dysfunction and exercise capacity in angina patients.
- Allopurinol decreases oxidative stress and may improve outcomes in heart failure patients.
Conclusions:
- Allopurinol's dual action—lowering uric acid and scavenging free radicals—makes it a promising therapeutic agent for CVD.
- Further research supports allopurinol's potential role in managing ischemic heart disease and congestive heart failure.
- Allopurinol may offer a novel approach to managing cardiovascular disease by targeting underlying biochemical pathways.
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...